Analyzing Waters (NYSE:WAT) and Bluejay Diagnostics (NASDAQ:BJDX)

Waters (NYSE:WAT) and Bluejay Diagnostics (NASDAQ:BJDX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Waters and Bluejay Diagnostics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Waters	0	8	9	3	2.75
Bluejay Diagnostics	1	0	0	0	1.00

Waters presently has a consensus target price of $387.53, indicating a potential upside of 18.35%. Given Waters’ stronger consensus rating and higher possible upside, analysts plainly believe Waters is more favorable than Bluejay Diagnostics.

Risk and Volatility

Waters has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Bluejay Diagnostics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.

Valuation & Earnings

This table compares Waters and Bluejay Diagnostics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Waters	$3.17 billion	10.16	$642.63 million	$10.77	30.40
Bluejay Diagnostics	N/A	N/A	-$6.85 million	($472.64)	0.00

Waters has higher revenue and earnings than Bluejay Diagnostics. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Waters and Bluejay Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Waters	20.30%	34.79%	16.29%
Bluejay Diagnostics	N/A	-145.52%	-115.63%

Institutional and Insider Ownership

94.0% of Waters shares are held by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are held by institutional investors. 0.8% of Waters shares are held by insiders. Comparatively, 0.1% of Bluejay Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Waters beats Bluejay Diagnostics on 14 of the 14 factors compared between the two stocks.

About Waters

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.